 |
English
|
正體中文
|
简体中文
|
Post-Print筆數 : 27 |
Items with full text/Total items : 114105/145137 (79%)
Visitors : 52188251
Online Users : 101
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/101021
|
| Title: | 論生物相似性藥品上市審查規範：以美國生物藥品價格競爭與創新法為師或為鑒？ |
| Other Titles: | On Regulation of Biosimilar: A Model or a Lesson by the U.S. Biologics Price Competition and Innovation Act of 2009? |
| Authors: | 傅冬卿;陳鋕雄
Fu, Dung-Ching;Chen, Chih-Hsiung |
| Keywords: | 生物相似性藥品;資料專屬權;營業秘密;相仿性研究;參考藥品
Biosimilar;Data Exclusivity;Trade Secret;Comparability Study;Reference Drug |
| Date: | 2013-12 |
| Issue Date: | 2016-08-31 17:10:57 (UTC+8) |
| Abstract: | 2010年10月23日美國歐巴馬政府簽署公告「生物藥品價格競爭與創新法」，正式開始全球最大單一藥品市場對生物相似性藥品的明文規範。從專利或競爭的方面來看，生物相似性藥品類似於學名藥，因係參考原開發商一已獲准上市之特定生物藥品，故在生物相似性藥品上市前需要考量參考藥品是否有專利保護、原開發商是否被主管機關賦予一市場專屬或資料專屬的行政保護期間。但從技術的本質來看，生物相似性藥品跟學名藥截然不同，前者的結構遠較後者複雜，學名藥得以簡易上市之前提在於證明學名藥與特定（小分子）藥品相等，而現今的技術僅能證明生物相似性藥品與特定生物藥品相似。美國聯邦政府於2012年預算計畫中倡議「生物藥品價格競爭與創新法」所規定的市場專屬期間應縮短為7年以節省政府支出。2012年2月美國藥政主管機關依法公開生物相似性藥品相關指引後，生物藥品原開發商亞培旋即於4月表達其反對該法施行之立場及論據。隨著90年代上市的生物藥品相關專利將陸續到期，生物相似性藥品的上市審查法規成為各藥品開發商關注的焦點，本文認為美國「生物藥品價格競爭與創新法」誕生於其特定的環境，我國的相關規範除了呼應技術的本質及進展外，更應該與我國產業現況一致。
The President Obama of United States signed the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) into law on October 23rd, 2010, and initiated the official regulation of biosimilar by the largest single pharmaceutical market in the world. From the perspective of patent or competition, biosimilar is similar to generics, because it references to a specific approved product as well. Likewise, whether there is patent or exclusivity covered the reference product is an issue to be considered in approving a biosimilar. However, from the perspective of technical nature, biosimilar and generics are totally different, because the structures of biologics are so complicated that different products can only be proved similarity or comparability, but not sameness, which is the prerequisite of the abbreviated approach in approving generics. In the budget of the U.S. government for fiscal year 2012, Obama administration proposed to reduce the 12 years of exclusivity for biologics to 7 years to control governmental expenditure. After the U.S. Food and Drug Administration published relevant guidelines for Biosimilar, Abbott Laboratories, one of the innovators of biologics, opposed the execution of BPCI Act. As the patents covered the biologics launched in 90`s expiring, the regulation of biosimilar is gaining attention. This article advocates the BPCI Act was fostered in a particular American political environment which does not exist in Taiwan. The regulatory policy of Taiwan shall echo not only the evolving technical nature, but also the industrial circumstances faced by Taiwan. |
| Relation: | 政大智慧財產評論, 11(2), 107-171
NCCU Intellectual Property Review |
| Data Type: | article |
| Appears in Collections: | [智慧財產評論] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| index.html | | 0Kb | HTML2 | 625 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
著作權政策宣告 Copyright Announcement1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.
2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(
nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(
nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
